Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 2Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Neuroendocrine Tumors 11Gastro-enteropancreatic neuroendocrine tumor 2Pheochromocytoma 1Paraganglioma 1Meningioma 1Glioblastoma 1Extensive Stage Small Cell Lung Cancer 1Carcinoma, Neuroendocrine 1Carcinoma, Merkel Cell 1Carcinoma 1Carcinoid Tumor 1Advanced Neuroendocrine Neoplasm 1Adenoma, Islet Cell 1

Interventions

Temozolomide 2Capecitabine 2lutetium Lu 177 dotatate 1cabozantinib 1atezolizumab 1abemaciclib 1X-Rays 1Specimen Handling 1Phantoms, Imaging 1Magnetic Resonance Spectroscopy 1Immunoglobulin G 1Disulfides 1Bevacizumab 111-(2-methylpropyl)-12,13-dihydro-2-methyl-8-(pyrimidin-2-ylamino)-4H-indazolo(5,4-a)pyrrolo(3,4-c)carbazol-4-one 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Adenoma, Islet Cell × lutetium Lu 177 dotatate × Clear all
NCT05247905 2025-04-02

Comparing Capecitabine and Temozolomide in Combination to Lutetium Lu 177 Dotatate in Patients With Advanced Pancreatic Neuroendocrine Tumors

Alliance for Clinical Trials in Oncology

Phase 2 Active not recruiting
31 enrolled

Adenoma, Islet Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡